drugset / Trial / NCT05367401
A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is to determine the safety and preliminary efficacy of sabatolimab in combination with magrolimab and azacitidine in adult participants with 1L unfit Acute Myeloid Leukemia (AML) or with 1L higher risk Myelodysplastic Syndromes (MDS), and sabatolimab in combination with magrolimab in participants with relapsed or refractory (R/R) AML.
Timeline
- Start
- 2024-12-20
- Primary completion
- 2029-10-26
- Completion
- 2029-10-26
Outcome
Outcome not reported
Stopped: “waiting for update from Study Lead”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Magrolimab | Monoclonal antibody | — | Intravenous |
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |